The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema
Table 1
Demographics, visual acuity, and macular thickness of patients with uveitic cystoid macular edema treated with intravitreal bevacizumab.
IIU
BD
IPU
POTBU
value
Number of patients
10
9
10
12
Mean age
44 ± 16
34 ± 7
28 ± 13
43 ± 17
Mean followup
4 ± 1
4 ± 1
4 ± 1
3.9 ± 2
Mean number of Avastin injections
1.2 ± 0.4
1.7 ± 0.7
1.6 ± 0.7
1.6 ± 0.5
Mean initial VA
0.5 ± 0.8
0.8 ± 0.8
0.8 ± 0.8
0.8 ± 0.5
Mean 1-month VA
0.3 ± 0.4
0.4 ± 0.8
0.5 ± 0.8
0.5 ± 0.8
Mean 3-month VA
0.2 ± 0.4
0.2 ± 0.5
0.3 ± 0.5
0.4 ± 0.5
<0.002
Mean initial OCT thickness (m)
437 ± 121
433 ± 179
342 ± 83
404 ± 134
Mean OCT thickness (1 month) (m)
314 ± 120
259 ± 102
270 ± 45
296 ± 94
Mean OCT thickness (3 months) (m)
246 ± 80
284 ± 106
239 ± 49
281 ± 110
<0.001
value (ANOVA) was assessed for the mean OCT retinal thickness and the mean LogMAR change in visual acuity form baseline. IIU: idiopathic intermediate uveitis, BD: Behcet’s disease, IPU: idiopathic panuveitis, POTBU: presumed ocular tuberculosis uveitis, VA: visual acuity, and OCT: optical coherence tomography.
